文献速递新发突发、热带与寄生虫病

坦桑尼亚西北部青蒿素部分耐药的证据:耐药性的临床与分子标志物

Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance.
PubMed 文献 · Lancet Infect Dis · 2024-08-16

该单臂疗效研究于2022年在坦桑尼亚卡盖拉区卡拉圭县开展,176例6月龄至120月龄恶性疟患儿分别接受蒿甲醚-苯芴醇或青蒿琥酯-阿莫地喹治疗。两种方案PCR校正治愈率分别为98%和100%,但第3天持续疟原虫血症及k13 Arg561His突变携带者中位清除半衰期提示青蒿素部分耐药存在。

要点

  • 蒿甲醚-苯芴醇组PCR校正治愈率98%(95%CI 91-100),青蒿琥酯-阿莫地喹组100%(96-100)。
  • 第3天持续疟原虫血症:蒿甲醚-苯芴醇组11/88(13%),青蒿琥酯-阿莫地喹组17/88(19%)。
  • 携带Arg561His突变者中位清除半衰期:蒿甲醚-苯芴醇组6.1小时,青蒿琥酯-阿莫地喹组6.0小时。

核心结论

  • 本研究证实坦桑尼亚存在青蒿素部分耐药(ART-R),尽管蒿甲醚-苯芴醇和青蒿琥酯-阿莫地喹均显示高疗效。
  • 亟需制定针对具体情况的应对策略并保持警惕,以发现当前抗疟药疗效降低及该国其他地区出现的ART-R。

研究设计与样本

  • 单臂疗效研究,在坦桑尼亚西北部卡盖拉区卡拉圭县Bukangara dispensary开展。
  • 纳入6月龄至120月龄、确诊恶性疟原虫无性体血症并符合WHO标准方案其他入选标准的参与者。
  • 参与者序贯接受蒿甲醚-苯芴醇或青蒿琥酯-阿莫地喹治疗,按WHO方案进行28天临床和寄生虫学评估。
  • 2022年4月29日至9月1日筛查343例,入组176例,每组88例。
  • 主要终点为PCR校正治愈率。

主要发现

  • PCR校正治愈率:蒿甲醚-苯芴醇组98%(95%CI 91-100),青蒿琥酯-阿莫地喹组100%(96-100)。
  • 第3天持续疟原虫血症:蒿甲醚-苯芴醇组11/88(13%),青蒿琥酯-阿莫地喹组17/88(19%)。
  • 第0天Arg561His突变且第3天有疟原虫血症:蒿甲醚-苯芴醇组8/87(9%),青蒿琥酯-阿莫地喹组10/86(12%)。
  • 携带Arg561His突变虫株患者的中位寄生虫清除半衰期:蒿甲醚-苯芴醇组6.1小时,青蒿琥酯-阿莫地喹组6.0小时。
  • 携带Arg561His突变的寄生虫与东南亚和卢旺达的虫株不相似,但与2021年坦桑尼亚同一卡盖拉地区报告的寄生虫单倍型相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2021, nationwide malaria molecular surveillance revealed a high prevalence of a validated artemisinin resistance marker, the kelch13 (k13) Arg561His mutation, in the Kagera region of northwestern Tanzania. We aimed to investigate the efficacy of artemether-lumefantrine and artesunate-amodiaquine and to confirm the presence of artemisinin partial resistance (ART-R) in the Karagwe district of this region. METHODS: This single-arm, therapeutic efficacy study was carried out at the Bukangara dispensary in the Karagwe district of the Kagera region in northwestern Tanzania. Eligible participants were aged between 6 months and 120 months, had confirmed Plasmodium falciparum asexual parasitaemia, and met other inclusion criteria according to WHO's standard protocol. Participants were enrolled, treated sequentially with either artemether-lumefantrine or artesunate-amodiaquine, and assessed clinically and parasitologically for 28 days as per WHO protocol. Parasitaemia was measured every 8 h until day 3, on day 7, and then during weekly follow-up visits until day 28. Mutations in the k13 gene and extended haplotypes with the mutations were analysed, and comparisons were made with previous samples collected in the same region of Kagera and in Rwanda and southeast Asia. The primary endpoint was PCR-corrected cure rate. FINDINGS: Between April 29 and Sept 1, 2022, 343 patients were screened, of whom 176 were enrolled: 88 in each treatment group. The PCR-corrected cure rate was 98% (95% CI 91-100) in the artemether-lumefantrine group and 100% (96-100) in the artesunate-amodiaquine group. Persistent parasitaemia on day 3 occurred in 11 (13%) of 88 patients in the artemether-lumefantrine group and 17 (19%) of 88 patients in the artesunate-amodiaquine group. Arg561His mutations on day 0 and parasitaemia on day 3 were reported in eight (9%) of 87 patients in the artemether-lumefantrine group and ten (12%) of 86 patients in the artesunate-amodiaquine group. The median parasite clearance half-life in patients harbouring parasites with Arg561His mutation was 6·1 h in the artemether-lumefantrine group and 6·0 h in the artesunate-amodiaquine group. Parasites with the Arg561His mutation were not similar to those from southeast Asia and Rwanda but had similar haplotypes to parasites reported in the same Tanzanian region of Kagera in 2021. INTERPRETATION: This study confirms the presence of ART-R in Tanzania, although artemether-lumefantrine and artesunate-amodiaquine showed high efficacy. A context-specific response strategy and vigilance to detect the reduced efficacy of current antimalarial treatments and ART-R in other parts of the country are urgently needed. FUNDING: The Bill & Melinda Gates Foundation and the US National Institutes of Health.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Ishengoma DS, Mandara CI, Bakari C, et al. Evidence of artemisinin partial resistance in northwestern Tanzania: clinical and molecular markers of resistance. Lancet Infect Dis. 2024. PMID: 39159633. doi:10.1016/S1473-3099(24)00362-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。